Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways is a research paper published in Aging (2021). On theSindex it has a DataRank of 0. It has been cited 31 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R21 CA226303
NIGMS NIH HHS
Grant: T32 GM007281
NCI NIH HHS
Grant: P30 CA014599
NCATS NIH HHS
Grant: UL1 TR000430
National Institutes of Health
Grant: 5R21CA226303-02
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
National Institutes of Health
Grant: 2T32GM007281-36
Medical Scientist National Research Service Award
National Institutes of Health
Grant: 3P30CA014599-36S1
Cancer Center Support Grant
National Institutes of Health
Grant: 2UL1TR000430-06
Re-Engineering Translational Research at the University of Chicago
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Modeling lung diseases using reversibly immortalized mouse pulmonary alveolar type 2 cells (imPAC2)
Additional file 1 of Modeling lung diseases using reversibly immortalized mouse pulmonary alveolar type 2 cells (imPAC2)